Xenon Pharmaceuticals Inc. (XENE)

NGM – Цена в реальном времени. Валюта: USD

59.74

+2.96 (5.21%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

60.10

+0.36 (0.60%)

После закрытия: Jun 26, 2026, 4:54 PM EDT

29.05.2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

14.05.2026

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

09.05.2026

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.

08.05.2026

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

08.05.2026

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

07.05.2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.

07.05.2026

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

Видео

No Data

There is no data to display

Пресс-релизы

29.05.2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07.05.2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

07.05.2026

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

01.05.2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 25,600 share options and 15,000 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of April 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Inc. (XENE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Видео

No Data

Пресс-релизы

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Видео

No Data

Пресс-релизы

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Xenon Pharmaceuticals Inc. (XENE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Видео

No Data

Пресс-релизы

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Видео

No Data

Пресс-релизы

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)